Variants of Gastric Carcinoma: Morphologic and Theranostic Importance

Lee, Sun-Mi; Kim, Kyoung‐Mee; Ro, Jae Y.

doi:10.5772/54342

Gastric Carcinoma- New Insights Into Current Management 2013

DOI: 10.5772/54342

|View full text |Cite

Variants of Gastric Carcinoma: Morphologic and Theranostic Importance

Sun-Mi Lee¹,

Kyoung‐Mee Kim²,

Jae Y. Ro³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 178 publications

(198 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Parietal cell/oncocytic gastric carcinoma: systematic review and first-time assessment of HER2 status in two new cases

Saffioti

et al. 2020

annals

View full text Add to dashboard Cite

Introduction Parietal cell/oncocytic gastric carcinomas are very rare and various aspects of this group remain unclear. The human epithelial growth factor receptor 2 (HER2) status of these tumours is largely unknown. Methods We performed a systematic electronic search of the literature and clinicopathological presentation of two cases including first-time complete assessment of HER2 status. Thirty-two patients with a mean age of 64.3 years, 87.5% of whom were male, were included in this review. Findings Half of the cases were recorded in Asia. Median follow-up was 24 months. There was no predominant site of development, while underlying histological abnormalities were present in 25%. At initial presentation, lymph node involvement was evident in 46.6% while distant metastatic disease was present in 9.3%. Presentation at stage I occurred in 55.6%. Potentially curative surgical/interventional treatment was intended in 90.6%. Recurrence occurred in 6.6%, while death was recorded in 19.2%, with cancer-related deaths reaching 11.5%. The one- and three-year survival rates were 84.2% and 79%, respectively. Our two cases displayed negative HER2 expression. Conclusions This systematic review demonstrates that this group of malignancies is very rare but possibly underdiagnosed. The disease commonly presents at early stage, mainly affecting middle-aged men. The prognosis is generally favourable even in cases of advanced disease. The HER2 expression and its correlation with the outcomes need to be further explored.

show abstract

Parietal cell/oncocytic gastric carcinoma: systematic review and first-time assessment of HER2 status in two new cases

Saffioti

et al. 2020

annals

View full text Add to dashboard Cite

show abstract

Experience of long-term clinical observation of a patient with a rare type of stomach cancer – lymphoepithelioma-like carcinoma

et al. 2020

View full text Add to dashboard Cite

Stomach cancer is one of the most frequently diagnosed cancers. The success of special methods of treatment are still disappointing in this disease, and stomach cancer has historically been considered a tumor refractory to treatment. Therefore, this category of patients, especially in the stage of dissemination, in most cases, palliative therapy is recommended. In recent years, the use of systemic chemotherapy and targeted therapy has led to a significant improvement in the quality of life and survival rates for stomach cancer compared to palliative therapy. However, significant progress in diagnostic methods over the past two decades has made it possible and possible to review approaches to the treatment of many cancer diseases that are refractory to chemotherapy. The last 2 decades, due to improved methods of diagnosis have allowed to revise approaches to the treatment of many refractory to chemotherapy of neoplastic diseases. In particular, the literature describes cases of revision and changes due to pre-existing diagnosis of IHC Research (carcinoid, NEO, stomach cancer, pancreatic cancer). This communication allows to share their own long experience of observation and treatment of a patient with a rare form of stomach cancer – lymphoepithelioma-like carcinoma.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Variants of Gastric Carcinoma: Morphologic and Theranostic Importance

Cited by 2 publications

References 178 publications

Parietal cell/oncocytic gastric carcinoma: systematic review and first-time assessment of HER2 status in two new cases

Parietal cell/oncocytic gastric carcinoma: systematic review and first-time assessment of HER2 status in two new cases

Experience of long-term clinical observation of a patient with a rare type of stomach cancer – lymphoepithelioma-like carcinoma

Contact Info

Product

Resources

About